J’Onco Mentor Version 9.09 — ENDOMETRIUM PRIMARY

Desktop version. Mobile app coming.

DIAGNOSIS YEAR

Select the diagnosis year first. J’Onco Mentor uses it to establish the standards cycle and to drive year-sensitive routing in this module.

SEER manual—
NAACCR cycle—
Staging context—
Standards statusSelect year
No diagnosis year selected. Year-dependent schema, staging, SSDI, grade, surgery, and manual guidance should not be assumed.

INTERACTIVE CORPUS UTERI / ENDOMETRIUM ANATOMY

Select one or more involved corpus uteri subsites. Selecting multiple areas does not automatically change the primary site to C54.8.

Primary site: —
Involved subsites: —
Coding rule: If the point of origin is known, retain that specific C54.x primary site and record other selected areas as additional involvement. Use C54.8 only when a single tumor overlaps adjacent subsites and the point of origin cannot be determined.

HISTOLOGY / SCHEMA ROUTING

Type a histology code or name, or browse the full dropdown below. Both controls stay synchronized.
Expanded corpus/endometrium histology list
Includes carcinoma/carcinosarcoma, adenosarcoma, uterine sarcomas, rare epithelial tumors and reportable precursor terminology. Verify rare site-morphology combinations in current Cancer PathCHART/SEER*RSA.

SCHEMA RESULT

—

Select a histology.

Current SEER*RSA separates corpus uteri cases into Carcinoma/Carcinosarcoma, Adenosarcoma, and Sarcoma schemas based on histology. The dropdown is intentionally broader than the most-common-histology list so rare valid corpus histologies are not omitted.

MYOMETRIAL INVASION HELPER

—
Enter measurements.
Use pathology when available. This helper calculates the percentage only; final AJCC/FIGO assignment must follow the diagnosis-year staging rules and documented anatomic extent.

AJCC STAGING SCHEMA

PATHOLOGIC STAGING CRITERIA — ENDOMETRIUM

Qualifying evidence: Hysterectomy generally provides definitive pathological assessment of myometrial invasion, cervical stromal involvement and other relevant tumor extent. Regional lymph node pathology supports pN where applicable. Check histology-specific staging rules and treatment sequence.

pT / pN: Assign only categories supported by the actual pathological evidence and the site-specific AJCC rules. A diagnosis-confirming biopsy does not automatically establish a pathological primary tumor category.

pM: Pathologically proven distant metastasis may support pM1 where the chapter permits; AJCC does not use pM0.

Treatment sequence: Distinguish initial pathological classification (pTNM) from post-neoadjuvant classification (ypTNM). Confirm eligibility, histology, staging chapter and diagnosis-year edition before finalizing.

Source / verification: AJCC · SEER tools and manuals. Educational overview only; verify exact chapter-specific criteria in the licensed AJCC manual.

Reference traceabilitySEER*RSA Corpus Uteri schemas ↗

Corpus Uteri AJCC / TNM Entry

Select the schema family that matches the documented histology, then enter T, N and M. Use the approved AJCC system for the final stage group.




AJCC / TNM RESULT

Schema—
T—
N—
M—

—

Histology determines which corpus uteri staging schema applies. Verify the final AJCC/FIGO stage group in the approved staging system.

REGIONAL LYMPH NODES

Pelvic nodes

Includes pelvic nodal groups used by the applicable corpus uteri schema. Record examined and positive pelvic nodes when required.

Para-aortic nodes

Record examined and positive para-aortic nodes separately when required by the schema/SSDI.

Do not infer a regional category from the phrase “retroperitoneal nodes” alone. Use the documented nodal chain and current SEER*RSA/AJCC definitions.

EOD / SUMMARY STAGE

EOD

Use the applicable corpus schema selected by site and histology. EOD Primary Tumor, EOD Regional Nodes and EOD Mets derive staging outputs according to SEER*RSA.

Summary Stage 2018

Use the diagnosis-year SEER*RSA derivation. Do not convert AJCC stage group directly to Summary Stage.

SURGERY — CORPUS UTERI (2026)

SEER note: Do not code D&C as Surgery of Primary Site for invasive corpus uteri cancers.
—
Select a procedure.

COMMON METASTATIC SITES — ENDOMETRIAL / CORPUS UTERI

Lung

Common distant site in advanced disease.

Liver

Recognized site of hematogenous spread.

Bone

Can occur in advanced or recurrent disease.

Peritoneum / distant nodes

May represent distant spread depending on the documented site and applicable staging system.

SOURCES

2027 standards cycle: Use the 2027 SEER Program Coding and Staging Manual, Solid Tumor Rules 2027, STORE 2027, NAACCR v27 resources, Summary Stage v3.4, and the current diagnosis-year SEER*RSA/EOD schema as applicable. Historical cases may require prior-year instructions.